Wells Fargo & Company Idera Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$0.23 - $0.43 $15 - $28	66 Added 20.37%	390 $0
Q3 2022 Nov 14, 2022	SELL	$0.38 - $0.53 $11 - $15	-30 Reduced 8.47%	324 $0
Q2 2022 Aug 12, 2022	BUY	$0.32 - $0.74 $9 - $21	29 Added 8.92%	354 $0
Q1 2022 May 16, 2022	BUY	$0.41 - $0.7 $0 - $0	1 Added 0.31%	325 $0
Q4 2021 Feb 14, 2022	SELL	$0.53 - $1.03 $529 - $1,028	-999 Reduced 75.51%	324 $0
Q3 2021 Nov 15, 2021	BUY	$1.0 - $1.18 $1,027 - $1,211	1,027 Added 346.96%	1,323 $1,000
Q2 2021 Aug 16, 2021	BUY	$1.01 - $1.58 $44 - $69	44 Added 17.46%	296 $0
Q1 2021 May 13, 2021	BUY	$1.23 - $5.98 $50 - $245	41 Added 19.43%	252 $0
Q4 2020 Feb 09, 2021	SELL	$2.09 - $5.18 $2,658 - $6,588	-1,272 Reduced 85.77%	211 $1,000
Q3 2020 Nov 05, 2020	BUY	$1.71 - $2.68 $34 - $53	20 Added 1.37%	1,483 $3,000
Q2 2020 Aug 13, 2020	SELL	$1.23 - $2.12 $533 - $920	-434 Reduced 22.88%	1,463 $2,000
Q1 2020 May 14, 2020	BUY	$1.06 - $2.15 $2,010 - $4,078	1,897 New	1,897 $2,000

Ticker IDRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,296,900
Market Cap $188M
Description
Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating s...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.